Compositions and methods for treating mucositis
US-2024415798-A1 · Dec 19, 2024 · US
Drug combinations and uses in treating a coughing condition
US9314465B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9314465-B2 |
| Application number | US-201414287014-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2014 |
| Priority date | Jun 16, 2009 |
| Publication date | Apr 19, 2016 |
| Grant date | Apr 19, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising 0.5 mg/mL to 10 mg/mL of Theobromine and 0.25 mg/mL to 7.5 mg/mL of Dextromethorphan, wherein the pharmaceutical composition does not include an anti-histamine. 2. The pharmaceutical composition according to claim 1 , wherein the composition comprises 0.5 mg/mL to 6 mg/mL of Theobromine and 0.5 mg/mL to 5 mg/mL of Dextromethorphan. 3. The pharmaceutical composition according to claim 2 , wherein the composition comprises 1 mg/mL to 3 mg/mL of Theobromine and 1 mg/mL to 3 mg/mL of Dextromethorphan. 4. The pharmaceutical composition according to claim 3 , wherein the composition comprises 2 mg/mL of Theobromine and 1.5 mg/mL of Dextromethorphan. 5. A method of treating cough, the method comprising the step of administering a therapeutically-effective amount of the pharmaceutical composition of claim 1 . 6. The method according to claim 5 , wherein the composition comprises 0.5 mg/mL to 6 mg/mL of Theobromine and 0.5 mg/mL to 5 mg/mL of Dextromethorphan. 7. The method according to claim 6 , wherein the composition comprises 1 mg/mL to 3 mg/mL of Theobromine and 1 mg/mL to 3 mg/mL of Dextromethorphan. 8. The method according to claim 7 , wherein the composition comprises 2 mg/mL of Theobromine and 1.5 mg/mL of Dextromethorphan. 9. The method according to claim 5 , wherein the therapeutically-effective amount of the pharmaceutical composition comprises between 20 mg/day and 200 mg/day of Theobromine and 10 mg/day and 150 mg/day of Dextromethorphan. 10. The method according to claim 9 , wherein the therapeutically-effective amount of the pharmaceutical composition comprises between 40 mg/day and 160 mg/day of Theobromine and 30 mg/day and 120 mg/day of Dextromethorphan.
Assignees
Inventors
Classifications
Morphinan derivatives, e.g. morphine, codeine · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/522Primary
having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9314465B2 cover?
- The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
- Who is the assignee on this patent?
- Infirst Healthcare Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/522. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).